Dendritic cell cancer vaccines have already become a treatment modality for patients with various cancer types. However, the curative potential of this immunotherapy is limited by the existence of negative feedback mechanisms that control dendritic cells (DCs) and T-cell function. By inhibiting the expression of inhibitory factors using RNA interference technology, a new generation of DC vaccines was developed. Vaccine-stimulated T cells showed antitumor effects both in vitro and in cancer patients. Here, we describe the development and validation of a fully GMP-compliant production process of ex vivo DC cancer vaccines combined with the blockade of immunosuppressive pathways using small interfering RNAs. The protocol can be used for DC-based therapy for all cancer types.
CITATION STYLE
Sæbøe-Larssen, S., & Sioud, M. (2020). Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference. In Methods in Molecular Biology (Vol. 2115, pp. 249–258). Humana Press Inc. https://doi.org/10.1007/978-1-0716-0290-4_14
Mendeley helps you to discover research relevant for your work.